Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Liver and energy benefits can be felt sooner by some people
Each has legitimate human evidence but targets narrower outcomes
Franco, J
All three are consistent with the observation that daily dosing of a short-half-life peptide produces robust and sustained tissue-repair effects in rodent models
Issue 1: Missing or Incorrect Modifier The single most common approval issue is submitting 96372 without the correct modifier when one is required
US$ 22.16
US$ 25.89
US$ 22.98
US$ 22.56
US$ 27.89
US$ 21.03
US$ 25.02
US$ 20.27
US$ 27.26
US$ 29.35
US$ 29.54
US$ 22.24
